What is the best approach to manage leukocytosis (elevated White Blood Cell count) in a patient with Systemic Lupus Erythematosus (SLE)?

Management of Leukocytosis in Systemic Lupus Erythematosus

Leukocytosis in SLE patients requires immediate exclusion of infection before attributing it to disease activity or medication effects, as infection is the most critical differential diagnosis that directly impacts mortality. 1

Immediate Diagnostic Priorities

Rule Out Infection First

• Screen systematically for infections before escalating immunosuppression, as patients with SLE have higher infection rates, particularly with glucocorticoid and immunosuppressive therapy. 1
• Test for HIV, HBV, and HCV in patients with any personal risk factors before administering immunosuppressive medications. 1
• Perform tuberculosis testing according to CDC recommendations before initiating glucocorticoids and immunosuppressive drugs, especially in endemic areas (TB incidence 2.5-13.8% in endemic regions vs 0-1.4% in low-incidence areas). 1
• Consider CMV antigenaemia testing (reported in 18-44% of SLE patients), particularly in those receiving high-dose glucocorticoids, pulse methylprednisolone, or pulse cyclophosphamide, as CMV infection can mimic active SLE. 1

Assess for Medication-Induced Leukocytosis

• Glucocorticoid therapy is the most common cause of leukocytosis in SLE patients, as steroids induce demargination of neutrophils and are used in up to 80% of SLE patients. 2, 3
• Review current glucocorticoid dosing, as doses ≥7.5 mg/day prednisone equivalent significantly increase infection risk and should be minimized. 1, 4, 2

Evaluate for Lupus Disease Activity

• Obtain complete blood count, serum creatinine, proteinuria, urine sediment, anti-dsDNA antibodies, and complement levels (C3, C4) to assess disease activity. 1, 5
• Use validated disease activity indices (BILAG, ECLAM, or SLEDAI) to monitor lupus activity and detect flares. 4, 5
• Assess for new clinical manifestations including skin lesions, arthritis, serositis, or neurological symptoms that correlate with disease activity. 5

Management Algorithm Based on Findings

If Infection is Identified

• Treat infection aggressively with appropriate antimicrobials immediately. 5
• Consider temporarily holding or reducing immunosuppression while treating severe infection. 5
• Do not escalate immunosuppression empirically without comprehensive infectious workup. 5

If Glucocorticoid-Induced Leukocytosis

• Taper glucocorticoids to <7.5 mg/day prednisone equivalent as rapidly as clinically feasible, as cumulative glucocorticoid dose is clearly related to adverse effects including infection risk. 4, 2, 3
• Doses of 5.0-7.5 mg prednisone pose significant infection risk (adjusted HR 6.80,95% CI 2.17-21.27 compared to 0-2.5 mg). 6
• Initiate or escalate immunosuppressive agents (azathioprine, mycophenolate mofetil, or methotrexate) to facilitate glucocorticoid tapering. 5, 7

If Active Lupus Disease

• Ensure hydroxychloroquine is optimized at ≤5 mg/kg real body weight, as it reduces disease activity and mortality. 5, 7, 8
• For moderate to severe flares, use IV methylprednisolone pulses (250-1000 mg daily for 1-3 days) to provide immediate therapeutic effect while enabling lower starting doses of oral glucocorticoids. 5, 7
• Add immunosuppressive therapy based on organ involvement: methotrexate for skin/joint manifestations, mycophenolate mofetil for renal/non-renal disease, or cyclophosphamide for severe organ-threatening disease. 5, 7

Monitoring Requirements During Management

• Assess lymphocyte counts, as levels ≤1×10⁹/L are associated with increased infection risk. 1
• Monitor total IgG and subclass levels (IgG3 ≤60 μg/ml or IgG4 ≤20 μg/ml indicate increased infection risk) at initial assessment and during follow-up, particularly in patients on immunosuppressive drugs. 1
• Evaluate patients with inactive disease every 6-12 months, with more frequent monitoring when reducing immunosuppressive therapy. 1

Critical Pitfalls to Avoid

• Never assume leukocytosis is solely due to lupus activity without excluding infection first, as infection is a major cause of mortality in SLE patients. 1, 5
• Do not continue glucocorticoids at doses ≥7.5 mg/day indefinitely, as chronic damage is driven by flares, glucocorticoid exposure, and antiphospholipid antibodies. 9
• Avoid live vaccines in patients taking immunosuppressive drugs and/or glucocorticoids at doses >20 mg/day. 1
• Do not discontinue hydroxychloroquine unless there is a specific contraindication, as it is associated with significant reduction in mortality. 5, 8